U.S. Markets closed

The Zacks Analyst Blog Highlights: AbbVie, Starbucks, Phillips 66, Anheuser-Busch InBev and Square

Zacks Equity Research

For Immediate Release

Chicago, IL – October 2, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie ABBV, Starbucks SBUX, Phillips 66 PSX, Anheuser-Busch InBev BUD and Square SQ.

Here are highlights from Tuesday’s Analyst Blog:

Top Stock Reports for AbbVie, Starbucks and Phillips 66

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including AbbVie, Starbucks and Phillips 66. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

AbbVie’s shares have outperformed the Zacks Large-Cap Pharmaceuticals industry in the past three months (2% vs. -3.7%). The Zacks analyst believes that AbbVie’s key drug, Humira, is performing well on strong demand despite competition.

Imbruvica has multibillion-dollar potential. AbbVie has been successful in expanding approvals for its cancer drugs, Imbruvica and Venclexta. Moreover, the company has an impressive late-stage pipeline comprising products with multibillion-dollar potential, expected to be launched in the near term. Meanwhile, the acquisition of Allergan, if successful, should diversify AbbVie’s revenue base and accelerate its non-Humira business.

However, AbbVie’s shares have underperformed the industry so far this year. Sales erosion due to direct biosimilar competition to Humira in international markets is a big headwind in 2019. Also, costs to support expected new product/line extension launches should hurt profits this year.

Shares of Starbucks have gained 37.3% year to date, outperforming the Zacks Food & Restaurants industry’s rise of 26.1%. The Zacks analyst believes that this momentum will continue as the company reported solid third-quarter fiscal 2019 earnings and also raised its full-year view.

Notably, earnings surpassed estimates in each of the trailing five quarters. Robust Americas and CAP comps bode well. The company now anticipates global comps growth of nearly 4%. Non-GAAP EPS is expected to be $2.80-$2.82, up from $2.75-$2.79 guided previously. Meanwhile, Starbucks' business is rapidly growing in China, courtesy of innovative store designs and the success of the MSR program.

Also, operating fundamentals such as solid global footprint, successful innovation, best-in-class loyalty program and digital offerings are encouraging. However, operating margin contraction over the past few quarters has been a concern.

Phillips 66’s shares have gained 8.3% in the past six months, outperforming the Zacks Oil Refining and Marketing industry’s rise of 1.9%. The Zacks analyst believes that Phillips 66 is well positioned to gain from rising demand for midstream assets in the United States, where takeaway capacity constraint is a potent problem.

Precisely, with its oil and gas pipeline network spreading across 21,000 miles, the company is an industry leader in the midstream business. Moreover, Phillips 66 is committed toward returning cash to stockholders through dividend payments and share repurchases. Notably, since inception, the firm has returned more than $24 billion to shareholders.

However, a declining crude utilization rate has hurt refining operations. Also, uncertainties in the global market, owing to more than a year-long trade dispute between the United States and China, are likely to hurt demand for petrochemicals and refined petroleum products, affecting the firm’s chemical and refining businesses.    

Other noteworthy reports we are featuring today include Anheuser-Busch InBev and Square.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”

Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.

See them now >>

 Media Contact

Zacks Investment Research

800-767-3771 ext. 9339




Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Square, Inc. (SQ) : Free Stock Analysis Report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
Anheuser-Busch InBev SA/NV (BUD) : Free Stock Analysis Report
Phillips 66 (PSX) : Free Stock Analysis Report
Starbucks Corporation (SBUX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research